The ANKRD18B Knockout HeLa Polyclonal Cells product is a heterogeneous population of CRISPR/Cas9-edited HeLa cells designed for loss-of-function studies of the ANKRD18B gene. This polyclonal knockout pool enables investigation of ANKRD18B’s role without single-cell clonal artifacts. The gene disruption is achieved through CRISPR/Cas9-mediated targeting, generating a pool of cells with diverse editing outcomes that collectively lack functional ANKRD18B protein.
HeLa cells are an immortalized epithelial cell line originally derived from a cervical adenocarcinoma biopsy from Henrietta Lacks. As one of the most extensively characterized human cell lines, HeLa serves as a robust model for epithelial tumor biology, providing a consistent and reproducible background for gene disruption studies. Their rapid proliferation, ease of culture, and well-documented genomics make them an ideal host for investigating the molecular underpinnings of cancer.
ANKRD18B encodes a protein containing ankyrin repeat motifs, which are known to mediate protein-protein interactions. The protein is predicted to function as a molecular scaffold, assembling multiprotein complexes that regulate signal transduction and transcriptional responses. Although the specific binding partners and downstream effectors remain uncharacterized, pathway analysis suggests a potential connection to NF-??B signaling, a key regulator of immune and stress responses. Disruption of ANKRD18B may therefore impair the formation of signaling hubs, leading to altered cellular outcomes such as proliferation, differentiation, or apoptosis.
In the HeLa background, a widely used model of cervical adenocarcinoma, the ANKRD18B knockout provides a valuable tool to dissect the contribution of this scaffold protein to epithelial tumor cell biology. Given the reported association of ANKRD18B with hepatocellular carcinoma and its potential role in tumorigenesis, this model allows researchers to explore how loss of ANKRD18B affects cancer-related phenotypes such as proliferation, migration, and signal transduction in a robust cellular context. The polyclonal nature of the product avoids biases that may arise from single-cell clones, offering a more representative population-level response.
Typical applications include the validation of ANKRD18B knockout by western blotting and RT-qPCR, assessment of protein interaction networks via co-immunoprecipitation, and subcellular localization studies using immunofluorescence. Functional assays such as cell proliferation, migration, and transcriptional reporter assays enable detailed phenotypic analysis of ANKRD18B loss, supporting investigations into cancer cell signaling and drug target validation. This polyclonal model is particularly suited for high-throughput screening approaches where population-level effects are prioritized. For further technical details or to discuss custom projects, contact Ascent Research.
